Cox-2、P63蛋白在非小细胞肺癌中的表达及意义  

Expressions of Cox-2 and P63 Protein in Non-small Cell Lung Cancers and Their Meanings

作　　者：陈寿松[1] 肖同浩[1] 彭正银[1] 陈昕薇[1] 梁励玮[1] 

机构地区：[1]广州军区武汉总医院病理科,武汉430070

出　　处：《华南国防医学杂志》2007年第4期43-45,共3页Military Medical Journal of South China

基　　金：湖北省卫生厅科研基金(2005JX2B46)

摘　　要：目的探讨非小细胞肺癌(Non-small cell lung cancer,NSCLC)组织中环氧化酶-2(Cyclooxygenase2,COX-2)、P63的表达及其与临床病理因素的关系。方法应用免疫组织化学S-P法分别检测78例NSCLC,(43例鳞癌,35例腺癌)组织中COX-2、P63蛋白的表达情况。结果78例NSCLC组织中COX-2为61.5%(48/78)、P63阳性表达56.4%(44/78)其中腺癌阳性率为91.4%(32/35)明显高于鳞癌37.2%(16/43)(P<0.01);COX-2在有淋巴结转移的NSCLC阳性表达率86.7%,亦明显高于无淋巴结转移阳性率27.3%(9/33)(P<0.01);COX-2在临床分期Ⅰ、Ⅱ期中阳性表达为29.7%,明显低于Ⅲ、Ⅳ期中阳性表达90.2%(P<0.01)。P63蛋白在肺鳞癌组织中阳性表达率97%,而腺癌组织中阳性率则为14.3%(P<0.01);P63在有淋巴结转移的NSCLC中阳性率为57.8%,而无淋巴结转移的阳性表达率为54.5%(P>0.05);P63在临床分期Ⅰ、Ⅱ期NSCLC组织中阳性表达率为64.9%和P63Ⅲ、Ⅳ期中阳性表达率48.8%表达差异无显著性(P>0.05)。结论提示COX-2在NSCLC组织中的过度表达与肺腺癌的进展以及淋巴结转移,临床分期等有密切关系,P63在肺鳞癌组织中的高表达,提示可将P63检测作为鉴别低分化肺癌的参考指标。Objective To study the relationship of the expressions of cyclooxygenase 2（COX-2） and P63 protein in non-small cell lung cancers （NSCLC） with the clinical pathological factors of NSCLC. Methods The expressions of cox-2 and P63 protein in 78 cases of NSCLC were determined by immunohistochemical SP technique. Results The positive rates of COX-2 and P63 protein expressions in 78 cases of NSCLC were 61.5% （48/78） and 56. 4% （44/78） respectively. The positive rate （91.4%, 32/35） of COX-2 expression in the adenocarcinomas was significantly higher than that （37. 2% ,16/43） in the squamous cell carcinomas（P〈0. 01）. The positive rate （86. 7% ,39/45） of COX-2 expression in NSCLC with lymph node metastasis was significantly higher than that （27. 3% ,9/33） in NSCLC without lymph node metastasis（P〈0. 01）. The positive rate （29. 7%, 11/37） of COX-2 expression in the clinical stage Ⅰ-Ⅱ NSCLC was significantly lower than that （90. 2 % ,37/41 ）in the clinical stage Ⅲ-Ⅳ NSCLC （P〈0. 01 ）. The positive rate （90. 7% ,39/43） of P63 expression in the squamous cell carcinomas was significantly higher than that （14. 3 %, 5/35） in the adenocarcinomas（P〈0. 01）. The positive rate （57. 8% ,26/45） of P63 expression in NSCLC with lymph node metastasis was insignificantly higher than that （54. 5%, 18/33） in NSCLC without lymph node metastasis （P〉0. 05）. The positive rate （64. 9%, 24/37） of P63 expression in the clinical stage Ⅰ-Ⅱ NSCLC was insignificantly higher than that （48. 8% ,20/41） in the clinical stage Ⅲ-Ⅳ NSCLC （P〉0. 05）. Conclusion It is suggested that the over-expression of COX-2 in NSCLC is closely related to the development, metastasis and clinical stage of NSCLC. The over-expression of P63 protein is of reference value to differentiating the adenocarcinomas from squamous cell carcinomas in the patients with NSCLC.

关 键 词：肺肿瘤 环氧化酶-2 P63 免疫组织化学 

分 类 号：R734.2[医药卫生—肿瘤]